Jump to section
To democratize biopharma research and development.
Medical research advances at an astounding pace, but promising areas of research often go unfunded. The biotech industry is heavily siloed and anti-collaborative, and academic funding for therapeutic drugs is often awarded to established researchers over new talent. Enter Molecule, a decentralised platform aiming to use Web3 technology and NFTs to make it easier for researchers to find backers for their research projects without relying on established funding channels.
Molecule consists of a community of funders, a framework for the platform's NFTs which allow researchers to fundraise without having to establish a patent or a startup of their own, and a marketplace where researchers can request support from the funders. Funders can directly own and govern projects which result in treatments which are important to them. This approach has been taken up enthusiastically, with over 250 research projects and several large biotech decentralised organisations with millions of dollars in funding participating in the network.
Molecule has raised seed funding in a round led by Northpond Ventures. This investment will allow it to hire more engineering talent and to create an accelerator for biotech decentralized organisations using its platform, offering $100,000 grants in specific areas of research. In the long term the company hopes to grow to allow pharmaceutical companies and the general public to also invest directly in research projects.
Steph
Company Specialist at Welcome to the Jungle
Dec 2022
$7.5m
SEED
Jun 2022
$13m
SEED
This company has top investors
Paul Kohlhaas
(CEO)Also a Founding Steward at VitaDAO. Was Vice Chairman at Advanced Blockchain and Director of Business Development with ConsenSys.
Tyler Golato
(Chief Scientific Officer)Also Co-Initiator at VitaDAO. Was a Research Scientist at the National Institutes of Health and John Hpokins Bayview Medical Center.